Kate Lawrenson

University of Southern California — United States

Medicine · Health Sciences

46h-index8.2kcitations312works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(118), Cancer-related molecular mechanisms research(75), RNA modifications and cancer(61), RNA Research and Splicing(32), Prostate Cancer Treatment and Research(29)

Publications304 total

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer
npj Genomic Medicine·2025Open Access
13608 The Association between Endometriosis and Financial Toxicity- a Prospective Study
Journal of Minimally Invasive Gynecology·2025
The Association between Pathology Confirmed Versus Unconfirmed Endometriosis and Anxiety and Depression
Journal of Minimally Invasive Gynecology·2025
Pro-endometriosis macrophage release of IL-33 is key for endometriosis pain and lesion formation
2025Open Access
M2 Macrophages are Major Mediators of Germline Risk of Endometriosis and Explain Pleiotropy With Comorbid Traits
Advanced Science·2025· 1 citedOpen Access
Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus
Nature Communications·2025Open Access
Tumour extracellular vesicle surface Protein-mRNA integration assay for early detection of epithelial ovarian cancer
EBioMedicine·2025· 3 citedOpen Access
Abstract P3-04-07: Modeling BRCA1 and BRCA2 Mammary Tissues and Estrogen Positive Breast Cancer Using iPSC-Derived Organoid Models
Clinical Cancer Research·2025
CTC1-STN1-TEN1 controls DNA break repair pathway choice via DNA end resection blockade
Science·2025· 7 cited
Supplement Figure 2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2025Open Access
Table S1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2025Open Access
Table S3 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2025Open Access
Supplement Figure 1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2025Open Access
Table S2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2025Open Access
M2 Macrophages are Major Mediators of Germline Risk of Endometriosis and Explain Pleiotropy with Comorbid Traits
2024Open Access
Figure 6 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2024Open Access
Table S3 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2024Open Access
Supplement Figure 2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2024Open Access
Table S2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2024Open Access
Figure 4 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
2024Open Access
page 1 of 16Next →

Frequent Co-authors

Simon A. Gayther(27), Beth Y. Karlan(18), Jonathan P. Tyrer(13), Rosario I. Corona(13), Ian Campbell(11), Jan Lubiński(11), Julie M. Cunningham(10), Anna Jakubowska(10), Joe Dennis(9), Hoda Anton‐Culver(9), Daniel W. Cramer(9), Jennifer A. Doherty(9), Brooke L. Fridley(9), Marc T. Goodman(9), Estrid Høgdall(9), Diether Lambrechts(9), Susan J. Ramus(9), Ellen L. Goode(9), Matthew L. Freedman(9), Natalia Bogdanova(8)